Compare Chugai Pharmaceutical Co., Ltd. with Similar Stocks
Dashboard
1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 23.71%
- Healthy long term growth as Net Sales has grown by an annual rate of 10.71% and Operating profit at 16.94%
- Company has very low debt and has enough cash to service the debt requirements
2
With ROE of 25.14%, it has a very attractive valuation with a 6.62 Price to Book Value
3
Majority shareholders : Non Institution
Stock DNA
Pharmaceuticals & Biotechnology
JPY 12,267,195 Million (Large Cap)
26.00
NA
0.02%
-0.45
25.14%
6.43
Revenue and Profits:
Net Sales:
341,584 Million
(Quarterly Results - Jun 2026)
Net Profit:
116,331 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-15.29%
0%
-15.29%
6 Months
-20.34%
0%
-20.34%
1 Year
-7.34%
0%
-7.34%
2 Years
11.1%
0%
11.1%
3 Years
64.16%
0%
64.16%
4 Years
81.88%
0%
81.88%
5 Years
71.38%
0%
71.38%
Chugai Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.71%
EBIT Growth (5y)
16.94%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.50
Sales to Capital Employed (avg)
0.64
Tax Ratio
27.32%
Dividend Payout Ratio
103.14%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
55.96%
ROE (avg)
23.71%
Valuation key factors
Factor
Value
P/E Ratio
26
Industry P/E
Price to Book Value
6.62
EV to EBIT
18.08
EV to EBITDA
16.83
EV to Capital Employed
11.14
EV to Sales
9.12
PEG Ratio
1.68
Dividend Yield
0.03%
ROCE (Latest)
61.60%
ROE (Latest)
25.14%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
341,584.00
321,747.00
6.17%
Operating Profit (PBDIT) excl Other Income
175,367.00
171,469.00
2.27%
Interest
0.00
0.00
Exceptional Items
-5,000.00
-4,500.00
-11.11%
Consolidate Net Profit
116,331.00
115,418.00
0.79%
Operating Profit Margin (Excl OI)
484.70%
505.60%
-2.09%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 6.17% vs -7.09% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 0.79% vs -10.12% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,257,941.00
1,170,611.00
7.46%
Operating Profit (PBDIT) excl Other Income
624,442.00
575,572.00
8.49%
Interest
433.00
95.00
355.79%
Exceptional Items
-27,566.00
-8,992.00
-206.56%
Consolidate Net Profit
434,012.00
387,317.00
12.06%
Operating Profit Margin (Excl OI)
470.50%
464.60%
0.59%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 7.46% vs 5.33% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 12.06% vs 19.00% in Dec 2024
About Chugai Pharmaceutical Co., Ltd. 
Chugai Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






